• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1278196 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type( }1 \: e4 k* ~  ~) e
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
0 s% ?: o3 m& Y6 D! x+ Author Affiliations
. @4 f; Y: z8 S9 v# c: K# c3 Q" n$ y1 ^
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan 2 L  i& T) x" M3 [4 ?, \1 u  K
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 9 r/ f4 j: f, |; l$ m
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
0 s/ Q4 n- y7 C+ }4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan . h5 m, l2 g7 f& y. T
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan   {+ ?6 ?; G) q" E$ ]% z* f' r
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
* G6 M9 L: @9 _7 V% o1 ?' D  W7Kinki University School of Medicine, Osaka 589-8511, Japan ) q% n- B0 l9 W) N4 x: A
8Izumi Municipal Hospital, Osaka 594-0071, Japan . g2 a+ j/ t8 E) u2 y
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan 4 e0 P( O. o9 y, p/ J
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp # |& N- U/ z' U" Z' o2 \* c
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. ; _/ ]8 X* {1 q# K& Y7 c+ Z
5 x/ k! ~1 N; G- F& z- v4 K, w8 Z+ |
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type * l9 _3 w" ^: A! c9 C& ?
% M/ @. O# l$ ]6 M% s8 U% t
Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato
* G: V  w0 D4 M4 S+ q6 @8 b6 M! b  N7 I5 {* ~
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  
" s* U# @8 ~. @, V. z5 ?! U/ r3 m! [/ m6 [4 t( v) V+ B; d" H
Published online on: Thursday, December 1, 2011
9 z" r, Q6 Y5 l4 z. g* \5 p( v* f8 ]
Doi: 10.3892/ol.2011.507
* ?1 N/ A5 l" n- t3 ~( B6 N% T" v: k
Pages: 405-410
& x, W! N' \/ _9 g0 j2 Y, t
: n& C$ ]) _4 c/ I- c* }0 ^Abstract:
6 u6 J0 @9 i1 Q. w. f( GS-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.
6 \: w# _' P" Q 0 U& i+ F7 T# |- d  ]
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
# l" K7 l) r4 i# xF. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3
8 i% H4 O( K; Y& z: o  h+ Author Affiliations
& N4 c* r1 E9 E% D# Y1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
) F9 O* K' K$ b- g8 q2Department of Thoracic Surgery, Kyoto University, Kyoto
8 z. k; N' U2 U: L; }; i+ q5 X3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan , x+ c  c* C! X
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
; f5 B4 i5 k* s! nReceived September 3, 2010.
/ d3 I. E9 q$ L# J9 Q4 D, ~' wRevision received November 11, 2010.
! w1 W6 i5 C" j% p* X8 t) uAccepted November 17, 2010. * `3 O8 @+ G- a  @# Z" Y0 T/ t* W
Abstract8 z3 |( i7 ~/ a& E
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
" ?" ]$ h4 ~- a" OPatients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
! l& i- s- s; i" @' v- CResults: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression. # g8 k' `1 P: R0 Q- |( t
Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.
" S4 j7 Y4 d$ n7 ~
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。' [/ q$ `+ z! ]3 X* {. w8 P! y
今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?8 a! P# S" O' P! X) F
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy' ~' r0 S  \; P- G: E, R  k* J" `
http://clinicaltrials.gov/ct2/show/NCT01523587
) v) y) x0 L; w/ n" M& E
1 s; i( g! \9 L$ CBIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
% P, k" A- m6 x8 T) n8 Thttp://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 1 J) L, p# \7 r# U3 N

# t' x2 R- h/ K8 Q* I1 }从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。. D9 P9 m- s  ~
至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53 ( C/ f0 ^" l( M& D9 q( T
从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。2 V7 e2 g9 ^. x( [2 G3 Z" t8 s
至今为止,未出 ...

) n; ~8 k9 J3 r& g7 i0 y+ ^没有副作用是第一追求,效果显著是第二追求。3 n- @% z. E, M# x+ q
不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表